This study aims to evaluate the effect of a multidisciplinary six-minute walking group and activities on patients with dementia's physical activity levels, mobility, anxiety, and cognitive function. The primary objective of this study is to evaluate the effectiveness of a multidisciplinary six-minute walking group intervention-spearheaded by physiotherapists, occupational therapists, and psychologists-in enhancing physical activity, mobility, cognitive function, and functional independence among patients with dementia. A systematic review of existing evidence on the effectiveness of the existing interventions will be conducted to contextualise the findings, providing a robust benchmark for assessing the contribution of each therapeutic component.
Secondary Objectives:
1. Physiotherapy Impact: To determine the specific effects of physiotherapy on mobility, endurance, and balance in dementia patients using validated, objective measures.
2. Occupational Therapy Contribution: To evaluate the role of occupational therapy in improving functional independence and the ability to perform daily activities through targeted, task-oriented activities.
3. Psychological Impact: To assess the psychological benefits of the intervention, including reductions in anxiety and enhancements in mood and overall mental health, as a result of the psychologist-led component.
4. Dietary Support Role: To investigate the influence of integrated dietary support on physical activity levels, nutritional status, and overall health.
5. Feasibility and Scalability: To explore the practicality of integrating this multidisciplinary intervention into routine dementia care and assess its potential for broader application across similar settings.

开始日期2025-01-06

申办/合作机构

Oxleas NHS Foundation Trust

ISRCTN11422802 / CompletedN/A

Evaluation of a brief worry intervention for people with persecutory delusions: are groups an effective form of delivery?

开始日期2015-02-02

申办/合作机构

Oxleas NHS Foundation Trust

100 项与 Oxleas NHS Foundation Trust 相关的临床结果

登录后查看更多信息

0 项与 Oxleas NHS Foundation Trust 相关的专利（医药）

登录后查看更多信息

316

项与 Oxleas NHS Foundation Trust 相关的文献（医药）

2024-08-01·Journal of Interpersonal Violence

Investigating the Psychological Impact of Cyber-Sexual Harassment

Article

作者: Iroegbu, Marvin ; Parsons, Georgia ; O'Brien, Freya ; Muñoz, Luna Clara

The impact of cyber sexual harassment (CSH) on adult women and the factors influencing this impact are largely under-researched. Communication technologies provide novel means for people to threaten, communicate, and harass others. Victims of in-person sexual harassment (ISH) can experience negative symptoms of depression, anxiety, trauma, and negative body image. The current study explored the psychological impact of CSH in adult women to determine whether CSH predicts psychological difficulties. Adult female participants ( N = 136) took part in an online, cross-sectional study; 44% of participants had experienced CSH and this was associated with higher levels of depression, anxiety, trauma, and body image dissatisfaction. Younger victims, those who had been in a relationship for a shorter amount of time, those who had previously experienced of ISH, and those who had a higher number of social media followers were more likely to have experienced CSH. When controlling for demographic variables, CSH predicted anxiety, depression, trauma, and body image dissatisfaction; however, experience of ISH impacted upon body-image dissatisfaction over and above CSH. There is a need to routinely ask individuals accessing mental health services whether online interactions cause harm. Future research should examine these phenomena in more ethnically diverse samples.

2024-08-01·Psychological Medicine

Diagnosis and pharmacological management of attention deficit hyperactivity disorder in adults with and without intellectual disability: cohort study using electronic health records

Article

作者: Woods, Hannah ; Sheehan, Rory ; Leng, Jennifer ; Baksh, R Asaad

AbstractBackgroundAttention deficit hyperactivity disorder (ADHD) is increasingly diagnosed in adults. People with intellectual disability have higher rates of ADHD yet there is little evidence on the presentation and pharmacological treatment of ADHD in this population or how this differs from the general population.MethodsRetrospective cohort study using data from electronic health records. Adults with intellectual disability newly diagnosed with ADHD between 2007 and 2022 were matched to adults with ADHD without intellectual disability and their clinical features and treatments were compared.ResultsA total of 159 adults with ADHD and intellectual disability and 648 adults with ADHD without intellectual disability formed the dataset. Adults with intellectual disability had higher rates of psychiatric co-morbidity and spent more time under mental health services than those without intellectual disability. They were more likely to have recorded agitation, aggression, hostility, and mood instability, and less likely to have poor concentration recorded in the 12 months prior to the diagnosis of ADHD. Following diagnosis, people with intellectual disability were significantly less likely to be prescribed any medication for ADHD than controls without intellectual disability (adjusted odds ratio 0.60, 95% confidence interval 0.38–0.91), and were less likely to be prescribed stimulants (27.7% v 46.0%, p < 0.001).ConclusionsThe presence of behaviors that challenge in adults with intellectual disability may indicate co-occurring ADHD. Further work to define the safety and efficacy of medication for ADHD in adults with intellectual disability is needed to understand differences in prescription rates and to avoid inequities in care outcomes.

2024-04-26·International Journal for Quality in Health Care

Key lessons to improve care—factors contributing to delayed discharges and cost implications: medical conditions and rehabilitation delays at a tertiary rehabilitation center in Saudi Arabia

Article

作者: Gupta, Poonam ; Greenfield, David

项与 Oxleas NHS Foundation Trust 相关的新闻（医药）

2021-04-19

·BioSpace

Awakn Life Sciences Inc. Announces Two Key Appointments to Its Board of Directors

Toronto, Ontario--(News - April 19, 2021) - Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat addiction, announced today the appointment of Stephen Page and Professor John Papastergiou as independent non-executive directors to the Company's Board of Directors. Adding significant pharmaceutical and healthcare sector experience and independent board governance to Awakn. Stephen Page has worked in executive and Board of Director roles in the UK healthcare industry for over 30 years, most notably leading Priory Healthcare, the largest network of mental healthcare hospitals and clinics in the UK, through a period of rapid expansion and market dominance. He has led and successfully grown organizations in both public and private sectors including Oxleas NHS Trust in London (which focused on mental health), Nestor plc and Acorn Care and Education. As founding CEO of Acorn Care and Education, and supported by Phoenix Equity Partners, Steve built the company via acquisition and organic growth to be a leading national provider of special needs education and foster care. He led the sale to the Ontario Teachers' Pension Plan in 2010. Professor Papastergiou is an experienced pharmacist and clinical research scientist who has served as an advisor to several leading pharmaceutical organizations including Bayer, Pfizer, GSK, and AstraZeneca. His innovative research in point-of-care diagnostic testing and pharmacogenomics has led to the development and advancement of several tech start-up companies of which he also served as a board director. Professor Papastergiou holds Faculty appointments at the schools of Pharmacy at the University of Toronto and the University of Waterloo. In 2019, he was named by the International Forum on Advancement of Healthcare as one of the top 100 healthcare leaders globally and was also presented with the Ontario Pharmacists' Association Award for Excellence in Research and Academia. "We are pleased to welcome both Steve and John's significant experience and independent governance to our Board of Directors at this next stage of Awakn's evolution," said George Scorsis, Awakn's Chairman. "Both are highly respected and have extensive experience in up-scaling fast-growing companies in the mental health and biotechnology sectors, respectively. We look forward to their assistance in guiding us towards our objectives to develop and deliver psychedelics and psychedelic-assisted psychotherapy to radically change mental health services and deliver significantly better patient outcomes." Media enquiries: ROAD Communications Paul Jarman (paul@roadcommunications.co.uk) Anna Ramsey (anna@roadcommunications.co.uk) Investor enquiries: KCSA Strategic Communications Valter Pinto (Valter@KCSA.com) Tim Regan (TRegan@KCSA.com) About Awakn Life Sciences Inc. Awakn Life Sciences is a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat Addiction. Awakn is integrating psychedelic medicine into mainstream healthcare through Research, Digital, Clinics, and Ecosystems. | Twitter | LinkedIn To view the source version of this press release, please visit

并购

100 项与 Oxleas NHS Foundation Trust 相关的药物交易

登录后查看更多信息

100 项与 Oxleas NHS Foundation Trust 相关的转化医学

登录后查看更多信息